Published • loading... • Updated
GLP-1 drugs could reduce long-term sick leave: Study
The drugs were linked to savings of up to 1.5% of a worker’s salary as they cut illness-related absences over 30 days, researchers said.
- A National Bureau of Economic Research study using Danish data found GLP-1 drugs, including Ozempic and Wegovy, reduced long-term sick leave by 17 percent, saving workers up to 1.5 percent of their salary for absences exceeding 30 days.
- GLP-1 drugs work by suppressing appetite and increasing fullness, effectively managing weight but significantly reducing overall food intake. Patients without structured nutrition plans risk developing nutritional deficiencies and inadvertent muscle loss alongside fat loss.
- A new consensus published in Obesity Pillars emphasizes that effective treatment requires structured nutritional support. Experts recommend patients consume approximately 1.2 to 1.5 grams of protein per kilogram daily and perform approximately 150 minutes of moderate aerobic exercise weekly.
- "Proper nutrition that suits the Indian body type is a must," said Dr V Mohan, Chairman, Dr Mohan's Diabetes Specialities Centre, Chennai. Asian Indians face higher risks of muscle loss and require careful monitoring of B12 and other key nutrients.
- Continued nutritional support after treatment discontinuation is essential for preventing weight regain and preserving metabolic benefits. Ongoing research suggests these medications could reduce risks of cardiovascular disease and certain cancers, broadening their long-term health impact.
Insights by Ground AI
14 Articles
14 Articles
Top endocrinologists call for diet to become standard care with GLP-1 weight loss drugs for Indians
A new expert consensus recommends that every patient starting semaglutide or tirzepatide should receive structured nutritional counselling to preserve muscle, prevent nutrient deficiencies and sustain weight loss.
·Noida, India
Read Full Article
The skinny on GLP-1s
Semaglutide and tirzepatide are two injectable GLP-1s that have been approved by the FDA specifically for weight loss. GLP-1s (short for “glucagon-like peptide-1 receptor agonists”) mimic a natural hormone in the body that helps to regulate blood sugar levels and appetite. GLP-1s have been used for diabetes treatment since 2005 and for weight management since 2014, according to the American… Source
Coverage Details
Total News Sources14
Leaning Left2Leaning Right0Center11Last UpdatedBias Distribution85% Center
Bias Distribution
- 85% of the sources are Center
85% Center
15%
C 85%
Factuality
To view factuality data please Upgrade to Premium
